- Advances Partnership Aimed at Streamlining
Cannabis and CBD Cultivator Production, Safety Standards, and
Traceability While Increasing Brand Recognition -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing and nucleic acid-based technologies, today announced
that its CertainT® platform has added support for StrainSecure 2.0
by TruTrace Technologies, Inc. (CSE: TTT; OTCQB: TTTSF)
(“TruTrace”) that builds on the companies’ strategic sales,
marketing, and technology integration partnership to advance their
vision of an integrated, cannabis product validation and
authentication supply chain security solution for cannabis
companies. The two companies recently announced that Flora Growth
(“Flora”) will utilize their integrated solution be as part of
Flora’s global cannabis product validation platform. TruTrace is
the developer of a fully integrated blockchain platform for the
legal cannabis, food, and pharmaceutical industries.
StrainSecure 2.0 is designed specifically for the cannabis
industry and aims to demystify the seed-to-sale process for all
relevant stakeholders, including producers, distributors, shippers,
government agencies, and consumers, by powering commercial
standards via an immutable, shared ledger. Applied DNA’s CertainT
platform has been integrated into TruTrace’s StrainSecure software
platform since the launch of the companies’ strategic alliance in
January 2021.
“Integrating our two platforms brings a unique end-to-end
solution to the maturing international cannabis industry. With
regulations and compliance standards being implemented worldwide,
an integrated offering of StrainSecure 2.0 and CertainT can help
cannabis companies meet these standards and provide product
authenticity and transparency to end-user customers,” said John
Shearman, vice president of marketing and cannabis lead at Applied
DNA.
Applied DNA’s CertainT platform provides the physical tagging of
cannabis products using a unique molecular tag to represent the
brand and product. That tag is then tested at key nodes within a
domestic or international supply chain. All authentication and
chain-of-custody data are captured in the CertainT portal, which
integrates with the TruTrace platform and will support StrainSecure
2.0. The molecular tag can be applied to cannabis plants, oils,
lotions, tablets, edibles, and packaging to serve as an immutable
indicator of authenticity, origin, and provenance.
TruTrace’s blockchain-based SaaS software is designed to
guarantee product quality and strain genetics throughout global
supply chains. Protecting consumers and brands from contaminants
and counterfeiting is a key benefit of the platform.
Robert Galarza, CEO of TruTrace, stated, “Over the past two
years and after extensive work with key partners, such as Applied
DNA, we’ve gained a deep understanding of the new challenges facing
this industry. Version 2.0 of StrainSecure, as well as its
interoperability with CertainT, will allow us to provide clients
with turnkey tools specifically designed to support product
quality, traceability, customer engagement, and safety.”
Most software systems utilized in the industry are fragmented
and are built to manage internal operations, with very little
interoperability into secondary systems. This fragmentation leads
to increased administrative costs, reduced revenue, and increased
risks for stakeholders. To address some of these issues,
StrainSecure 2.0 will include several robust features tailored to
decrease administrative costs, increase revenue, scale business
operations, and highlight product quality. StrainSecure 2.0 also
includes a significant number of new features, including full
integration into the CertainT® platform, that facilitate higher
standards and fuels business growth. One such new feature is the
Enhanced Scan Page, which serves as a marketing tool for brands by
providing real-time data on products at the package level.
Galarza added, “The expectations of customers, as it relates to
the quality of the products they choose to consume, has never been
higher. StrainSecure 2.0 focuses on promoting good actors in the
industry and giving them a solution, which unifies their network,
mitigates risk, ensures compliance with commercial standards, and
creates a safer and more consistent marketplace for their
customers. Globally focused hemp and cannabis businesses equip
themselves with StrainSecure™ to scale their business.”
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies. Applied DNA has also established a
COVID-19 diagnostic and testing offering that is in the early
stages of commercialization and is grounded in the Company’s deep
expertise in DNA.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include Gov/Mil, textiles,
pharmaceuticals and nutraceuticals, and cannabis, among others.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under the ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
About TruTrace Technologies
TruTrace Technologies is the developer of fully-integrated
software, secured on a blockchain infrastructure, that gives
clients’ the ability to store, manage, share and immediately access
quality assurance and testing details, COAs, as well as motion and
movement intelligence on inventory. The platform was specifically
designed to power the traceability of testing standards within the
legal cannabis, nutraceutical, food and pharmaceutical space with a
focus on the authentication of source materials or ingredients used
in formulation. For more information, please visit
https://www.trutrace.co/.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
including Applied DNA’s ability to successfully enter into
commercial contracts for the implementation of its CertainT®
platform, shifting enforcement priorities of U.S. federal laws and
other international laws relating to cannabis and cannabis
derivative products, and various other factors detailed from time
to time in Applied DNA’s SEC reports and filings, including our
Annual Report on Form 10-K filed on December 17, 2020, and
Quarterly Reports on Form 10-Q filed on February 11, 2021, May 13,
2021, and August 12, 2021, and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210914005666/en/
Investor contact: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Program contact: John Sherman,
631-240-8838, john.sherman@adnas.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024